Biomarin Pharmaceutical (BSP:B1MR34) Operating Cash Flow per Share : R$10.14 (TTM As of Mar. 2025)

View and export this data going back to 2020. Start your Free Trial

What is Biomarin Pharmaceutical Operating Cash Flow per Share?

Biomarin Pharmaceutical's operating cash flow per share for the three months ended in Mar. 2025 was R$2.56. Biomarin Pharmaceutical's operating cash flow per share for the trailing twelve months (TTM) ended in Mar. 2025 was R$10.14.

During the past 12 months, the average Operating Cash Flow per Share Growth Rate of Biomarin Pharmaceutical was 144.40% per year. During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 20.50% per year. During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 45.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.

The historical rank and industry rank for Biomarin Pharmaceutical's Operating Cash Flow per Share or its related term are showing as below:

BSP:B1MR34' s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -50.2 Med: 20 Max: 144.4
Current: 20.5

During the past 13 years, Biomarin Pharmaceutical's highest 3-Year average Operating Cash Flow per Share Growth Rate was 144.40% per year. The lowest was -50.20% per year. And the median was 20.00% per year.

BSP:B1MR34's 3-Year OCF Growth Rate is ranked better than
62.41% of 1221 companies
in the Biotechnology industry
Industry Median: 9.3 vs BSP:B1MR34: 20.50

Biomarin Pharmaceutical Operating Cash Flow per Share Historical Data

The historical data trend for Biomarin Pharmaceutical's Operating Cash Flow per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomarin Pharmaceutical Operating Cash Flow per Share Chart

Biomarin Pharmaceutical Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Operating Cash Flow per Share

Get a 7-Day Free Trial

1.15

4.71

2.44

2.04

8.88

Biomarin Pharmaceutical Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Operating Cash Flow per Share	Get a 7-Day Free Trial															0.59	1.60	3.11	2.88	2.56

Competitive Comparison of Biomarin Pharmaceutical's Operating Cash Flow per Share

For the Biotechnology subindustry, Biomarin Pharmaceutical's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biomarin Pharmaceutical's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biomarin Pharmaceutical's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Biomarin Pharmaceutical's Price-to-Operating-Cash-Flow falls into.

Save Embed

;

Save Embed

;

Biomarin Pharmaceutical Operating Cash Flow per Share Calculation

Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.

Biomarin Pharmaceutical's Operating Cash Flow per Share for the fiscal year that ended in Dec. 2024 is calculated as

Operating Cash Flow per Share (A: Dec. 2024 )	=	Cash Flow from Operations (A: Dec. 2024 )	/	Shares Outstanding (Diluted Average) (A: Dec. 2024 )
	=	3494.903	/	393.416
	=	8.88

Biomarin Pharmaceutical's Operating Cash Flow per Share for the quarter that ended in Dec. 2024 is calculated as

Operating Cash Flow per Share (Q: Mar. 2025 )	=	Cash Flow from Operations (Q: Mar. 2025 )	/	Shares Outstanding (Diluted Average) (Q: Mar. 2025 )
	=	1004.178	/	392.948
	=	2.56

Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was R$10.14

Biomarin Pharmaceutical Operating Cash Flow per Share Related Terms

Thank you for viewing the detailed overview of Biomarin Pharmaceutical's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Biomarin Pharmaceutical Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biomarin Pharmaceutical Inc (BSP:B1MR34) » Definitions » Operating Cash Flow per Share

Comparable Companies

Traded in Other Exchanges

BMRN:USA 1BMRN:Italy 0HNC:UK BM8:Germany BMRN:Austria

Address

770 Lindaro Street, San Rafael, CA, USA, 94901

Website

https://www.biomarin.com

BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments aimed at addressing complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria (PKU), hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development.

Biomarin Pharmaceutical Headlines

No Headlines